Back to Search
Start Over
Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis: Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial
- Source :
- Ständer, S, Kwatra, S G, Silverberg, J I, Simpson, E L, Thyssen, J P, Yosipovitch, G, Zhang, F, Cameron, M C, Cella, R R, Valdez, H, DiBonaventura, M & Feeney, C 2023, ' Early Itch Response with Abrocitinib Is Associated with Later Efficacy Outcomes in Patients with Moderate-to-Severe Atopic Dermatitis : Subgroup Analysis of the Randomized Phase III JADE COMPARE Trial ', American Journal of Clinical Dermatology, vol. 24, pp. 97-107 . https://doi.org/10.1007/s40257-022-00738-4
- Publication Year :
- 2022
- Publisher :
- Springer Science and Business Media LLC, 2022.
-
Abstract
- Background: Abrocitinib, an oral Janus kinase 1 inhibitor, provided significant itch relief by week 2 in patients with moderate-to-severe atopic dermatitis (AD) in the phase III JADE COMPARE trial. Objectives: This post-hoc analysis of JADE COMPARE aimed to further characterize itch response and determined whether early itch relief could predict subsequent improvements in AD severity. Methods: JADE COMPARE was a randomized, double-blind, double-dummy, placebo-controlled trial. Adult patients (aged ≥ 18 years) with moderate-to-severe AD were randomly assigned to receive oral abrocitinib 200 mg or 100 mg once daily, subcutaneous dupilumab 300 mg every other week (after a 600-mg loading dose), or placebo, plus medicated topical therapy for 16 weeks. Assessments were ≥ 4-point improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) from days 2 to 15, Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA) response, and Dermatology Life Quality Index (DLQI) scores at week 12. Association between week 2 PP-NRS4 and efficacy at week 12 was evaluated by chi-squared tests. The predictive value of early response for later efficacy was assessed by area under the receiver operating characteristic curve. Results: As early as day 4 after treatment, a significantly greater proportion of patients achieved PP-NRS4 response with abrocitinib 200 mg (18.6%) versus dupilumab (5.6%; p
- Subjects :
- Dermatology
General Medicine
Subjects
Details
- ISSN :
- 11791888, 11750561, and 03720470
- Volume :
- 24
- Database :
- OpenAIRE
- Journal :
- American Journal of Clinical Dermatology
- Accession number :
- edsair.doi.dedup.....cbff8fe5570e6ed3bdcc5e9e4cc12de5